A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172) | Zendy

Hannah Kibuuka | Zendy; Robert Kimutai | Zendy; Leonard Maboko | Zendy; Fred Sawe | Zendy; Mirjam Schunk | Zendy; Arne Kroidl | Zendy; Douglas Shaffer | Zendy; Leigh Anne Eller | Zendy; Rukia Kibaya | Zendy; Michael A. Eller | Zendy; K. Schindler | Zendy; Alexandra Schuetz | Zendy; Monica Millard | Zendy; Jason R. Kroll | Zendy; Len Dally | Zendy; Michael Höelscher | Zendy; Robert T. Bailer | Zendy; Josephine H. Cox | Zendy; Mary Marovich | Zendy; Deborah L. Birx | Zendy; Barney S. Graham | Zendy; Nelson L. Michael | Zendy; Mark de Souza | Zendy; Merlin L. Robb | Zendy

Open Access

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

Author(s) -

Hannah Kibuuka,

Robert Kimutai,

Leonard Maboko,

Fred Sawe,

Mirjam Schunk,

Arne Kroidl,

Douglas Shaffer,

Leigh Anne Eller,

Rukia Kibaya,

Michael A. Eller,

K. Schindler,

Alexandra Schuetz,

Monica Millard,

Jason R. Kroll,

Len Dally,

Michael Höelscher,

Robert T. Bailer,

Josephine H. Cox,

Mary Marovich,

Deborah L. Birx,

Barney S. Graham,

Nelson L. Michael,

Mark de Souza,

Merlin L. Robb

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/650299

Subject(s) - virology , immunogenicity , vaccination , serotype , dna vaccination , neutralizing antibody , titer , hiv vaccine , medicine , immunology , biology , antibody , vaccine trial , virus , immunization

Human immunodeficiency virus (HIV) vaccine development remains a global priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a replication-defective recombinant adenovirus serotype 5 (rAd5) boost.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research